Micromedic – a Unique Cluster of Cancer Diagnostic Solutions     News
  Micromedic Technologies Ltd. specializes in the development and commercialization of innovative in vitro cancer diagnostic products and solutions. Our portfolio includes state-of-the-art technologies involving gene expression, biomarker and histochemical assays for early cancer detection and personalized medicine.
Micromedic offers proprietary diagnostic solutions for multiple cancer diagnostic applications, providing practical answers to real unmet needs.

Micromedic is a public company traded on the Tel Aviv Stock Exchange (TASE: MCTC).

 		   28-8-2017
Invitation to general assembly meeting

27-7-2017
Micromedic Announces routine use of CellDetect in additional CLIA Laboratory in the US

28-6-2017
Micromedic announces distribution agreement in Germany

24-5-2017
Micromedic announces significant purchase order from China

6-4-2017
Announcement of the annual general assembly of shareholders of Micromedic Technologies

27-11-2016
An extraordinary assembly of Micromedic's shareholders is scheduled on January 3rd, 2017 at 4pm in the Company's offices in Kyriat Atidim

24-11-2016
Micromedic announces approval to conduct an extended clinical study with CellDetect on prostate cancer diagnosis

19-7-2016
Announcement of an extraordinary assembly of shareholders of Micromedic Technologies

26-5-2016
Announcement of the annual general assembly of shareholders of Micromedic Technologies

10-1-2016
Micromedic Announces Receipt of Regulatory Approval to Commercialize CellDetect® Bladder Cancer Monitoring Kit in Israel

29-11-2015
Micromedic Announces Cooperation with Axella Research for Financing and Execution of Clinical and Regulatory Activities Required for FDA Approval of CellDetect® Bladder Cancer Monitoring

1-9-2015
Micromedic Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of BRONJ

30-6-2015
Micromedic Obtains EU CE Mark for CellDetect® Non-Invasive Test for Detecting Recurrence of Bladder Cancer

2-2-2015
Micromedic Reports Successful Clinical Study Results for Monitoring Bladder Cancer Recurrence

1-7-2014
Micromedic Reports Successful Interim Results from Bladder Cancer Clinical Study

27-5-2014
Micromedic identifies new genetic markers to predict risk of developing BRONJ

3-2-2014
Micromedic reports success in clinical pilot of its Cervical Cancer diagnostic product in a central hospital in Beijing

8-7-2013
Zetiq has signed a memorandum of understanding for collaboration in India

25-12-2012
Successful interim results in a trial of a test for recurrence of bladder cancer cells in urine specimens

3-10-2012
Zetiq receives patent approval in Japan for its cell staining technology

20-11-2012
Marketing approval for Zetiq's CellDetect in China

15-4-2012
BioLight will invest 4 million NIS for additional 5% of Micromedic

27-3-2012
Micromedic signed an investment agreement with BioMarCare Technologies Inc.

25-9-2011
BioLight acquires 21% of Micromedic
© Micromedic Technologies Ltd. site map | contact
 
Site by Site2goal | Design Studio Michal Lehavi